Immix Biopharma, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 15.43 million compared to USD 8.23 million a year ago. Basic loss per share from continuing operations was USD 0.89 compared to USD 0.59 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.125 USD | -3.41% | +11.46% | -69.08% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-69.08% | 5.81Cr | |
+2.97% | 9.47TCr | |
-3.68% | 3.73TCr | |
-11.55% | 3.27TCr | |
+74.21% | 2.77TCr | |
-13.94% | 1.62TCr | |
-2.17% | 1.39TCr | |
-12.21% | 1.16TCr | |
+188.83% | 1.09TCr | |
-53.94% | 954.09Cr |
- Stock Market
- Equities
- IMMX Stock
- News Immix Biopharma, Inc.
- Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023